⚡ Trade +10,000 CFDs with Tight Raw Spreads. – Trade Now!

Aspen Pharmacare Holdings Ltd. JSE: APN

R150.32 ▲ 0.15 (0.1%) Prices delayed 15 min · Last updated: 2026-07-17 17:05:00

Open

148.71

Prev close

150.32

Day range

148.03 - 150.35

Volume

1 115 869

52-wk range

144.14 – 160.40

Market cap

67.08bn

P/E Ratio

73.83

EPS (ZARc)

203.60

Dividend Yield

1.40%

DPS (ZARc)

211 (cps)

Price performance

Intraday — 7D — 1M — 3M — 6M — 1Y — 3Y — 5Y — YTD —

Loading chart…

Analyst consensus

Key statistics

Market cap67.08bn

EPS203.60

P/E ratio73.83

Div. yield1.40%

DPS 211 (cps)

Issued shares446.25m

52-week range

R 144.14 R 160.40

R150.32

Price overview

Open148.71

Previous close150.32

Day range148.03 - 150.35

Volume1 115 869

52-week range144.14 – 160.40

Change▲ 0.15 (0.1%)

P/E ratio73.83

EPS203.60

Dividend 211 (cps)

Dividend yield1.40%

Important dates

Final Div 2.11 ZAR

Decl 3 Sep 2025, LDT 30 Sep 2025
Final Div 2.11 ZAR

Decl 3 Sep 2025, Pay 6 Oct 2025
Dec 2025

Half Year
Jun 2025 Final

Released 3 Mar 2026
Dec 2025 Interim

Released 3 Mar 2026
Jun 2026

Prev Year End
Jun 2026 Final

Confirmed for 2 Sep
Next Expected Final Div 2.11 ZAR

Decl 3 Sep 2026, LDT 30 Sep 2026
Next Expected Final Div 2.11 ZAR

Decl 3 Sep 2026, Pay 6 Oct 2026
4 Dec 2026

AGM Unconfirmed
Dec 2026

Half Year
Dec 2026 Interim

Unconfirmed for 3 Mar
Jun 2027

Next Year End

Financial results

ZAR million	Dec 25	Dec 24R
Turnover	17 078	17 849
Attributable Income	1 472	2 388
Market Cap (ZARm)	52 117.50	73 209.90
EPS (ZARc)	331.10	537.70
HEPS (Cont Ops)(ZARc)	233.20	431.20
DPS (ZARc)	0	0

Latest SENS announcements

Aspen - proposed succession and board update

2026-07-09 12:04:43

Kuseni Dlamini has advised the Board that he will not make himself available for re-election as a director at the Company's annual general meeting to be held in December 2026 ('AGM'). Accordingly, he will step down as Chair of the Board and cease to serve as an independent non-executive director of the Company at the conclusion of the AGM. The Board has resolved to appoint Ben Kruger as successor Chair of the Board when Kuseni stands down as Chair at the conclusion of the AGM. He will step down from the Audit and Risk Committee when he takes over as Chair in December. Ben has been appointed as a member of the Remuneration and Nomination Committee. Chris Mortimer, a non-executive director, has informed the Board that he will not make himself available for re-election as a director at the AGM and will accordingly retire from the Board at the conclusion of that meeting. Dr Yvonne Muthien will attain the age of 70 in September 2026 and, in terms of the Company's Board Charter and Board Policy on Tenure, is deemed to retire at that age. The Board has, however, determined that it is in the best interests of the Company for Dr Muthien to continue serving as an independent non-executive director for a further year following the AGM, to maintain Board continuity. Themba Mkhwanazi, an independent non-executive director, has been appointed as a member of the Social and Ethics Committee with immediate effect.
Aspen Pharmacare Holdings Ltd. - Notification in t

2026-07-02 10:00:00

The company has issued a statement regarding an interest in shares.
Aspen Pharmacare Holdings Ltd. - Dealing in Securi

2026-06-25 16:00:00

A director has dealt in shares of the company.
Aspen - change in chair of committee

2026-06-22 16:05:28

The company announced a change in the chairmanship of its Audit and Risk Committee, in line with JSE Listings Requirements. Ben Kruger stepped down as chair effective 22 June 2026 but remains a member of the committee. Neo Dongwana was appointed as the new chair, also effective from 22 June 2026.
Aspen - completion of divestment of Aspen APAC

2026-05-29 08:51:20

Aspen completed the divestment of its Aspen APAC business, with all conditions precedent fulfilled as of 29 May 2026. The transaction consideration remained AUD2 370 million, with transaction costs under 5% of this amount. The Group received net proceeds of approximately R27 billion, primarily used to reduce debt, strengthening its balance sheet and increasing financial flexibility. The transaction reflects significant value creation, and the board believes the current share price undervalues Aspen’s underlying businesses and growth prospects. A webcast discussing these developments will be available at 12h30 SAST on 29 May 2026.

Peer comparison

Company	Price (ZAR)	Change	Market cap
ASPEN (APN)	R 150.32	+0.1%	—

People Also Watch

British American Tobacco plc

1,032.54

Mondi plc

168.18

Sasol Ltd.

188.21

Shaftesbury Capital plc

31.65

Aspen Pharmacare Holdings Ltd. Today's Verdict

Today's verdict: Aspen Pharmacare Holdings Ltd. shares look cautiously constructive at the current price today in rands of R148.45, with charts and historical graph readings pointing to steady growth rather than a sharp breakout. The latest data supports a measured price forecast and near-term prediction, though the buy or sell decision still depends on cost discipline, dividend expectations, and overall market appetite. For investors reviewing preference shares, payout quality, and for sale opportunities, the share code APN remains easy to check online through a trading account, making how to buy and trading execution straightforward on the JSE.

Aspen Pharmacare Holdings Ltd. Live Share Data

Label	Value
Share Name & Ticker	Aspen Pharmacare Holdings Ltd. (APN)
Exchange	JSE (Johannesburg Stock Exchange)
Sector & Industry	Healthcare / Pharmaceuticals
Current Price	R148.45
Market Capitalization	67.01bn
P/E Ratio	73.76
Dividend Yield	1.41%
Trading Volume (Live Data)	14 063
Recent Price Change	-1.15
Data as of	2026-07-17 09:49:01

Aspen Pharmacare Holdings Ltd. Key Highlights

Label	Value
Current Price	R148.45, down 1.15 from the previous close
Market Cap	67.01bn, indicating a large market presence
P/E Ratio	73.76, suggesting overvaluation
Dividend Yield	1.41%, attractive for income-focused investors
Volatility	Moderate, based on the latest price move and trading volume

Aspen Pharmacare Holdings Ltd. Limited Forecast Insights

The near-term setup looks mixed rather than decisive. A soft daily move of -1.15 alongside volume of 14 063 suggests the market is still digesting valuation at 73.76 times earnings. If buying interest improves, APN could stabilise around current levels; if not, momentum may stay capped.

FAQ on Aspen Pharmacare Holdings Ltd. Shares

Q1: What are Aspen Pharmacare Holdings Ltd. shares?
Answer: Aspen Pharmacare Holdings Ltd. shares are listed equity on the JSE under APN. The company has a market capitalisation of 67.01bn, a current price of R148.45, and operates in Healthcare / Pharmaceuticals, which frames how investors assess its value.

Q2: How can I buy Aspen Pharmacare Holdings Ltd. shares?
Answer: You can buy APN through a JSE-approved trading account using a broker or online platform. The live price today is R148.45, so any purchase should be based on that price per share, plus trading costs and your execution plan.

Q3: What affects the price of Aspen Pharmacare Holdings Ltd. shares?
Answer: The share price is affected by the current price of R148.45, the recent change of -1.15, trading volume of 14 063, and valuation at a P/E of 73.76. Sector sentiment in Healthcare / Pharmaceuticals also matters for APN.

Q4: Does Aspen Pharmacare Holdings Ltd. pay dividends?
Answer: Yes, Aspen Pharmacare Holdings Ltd. shows a dividend yield of 1.41%, which indicates it does pay dividends. Investors looking at APN can compare that payout against the current price of R148.45 and the company’s 67.01bn market capitalisation.

Q5: How can I track my Aspen Pharmacare Holdings Ltd. shares and dividends?
Answer: Track APN by monitoring the JSE quote, current price of R148.45, trading volume of 14 063, and dividend yield of 1.41%. A portfolio dashboard or trading account helps you follow shares, dividend updates, and price changes in one place.

Q6: What factors are affecting the Aspen Pharmacare Holdings Ltd. share price?
Answer: The main factors are the P/E ratio of 73.76, the recent price change of -1.15, and the latest trading volume of 14 063. Market cap at 67.01bn and the Healthcare / Pharmaceuticals sector also shape APN’s valuation.

Q7: Is Aspen Pharmacare Holdings Ltd. a good share to buy?
Answer: APN may suit investors who accept a higher valuation, since the P/E ratio is 73.76 and the price today is R148.45. The dividend yield of 1.41% adds income support, but the latest move of -1.15 calls for caution.

Q8: Is it advisable to buy Aspen Pharmacare Holdings Ltd. shares today?
Answer: Buying today is a judgment call based on APN’s R148.45 price, -1.15 daily change, and 14 063 volume. The data shows a large-cap Healthcare / Pharmaceuticals share with a 1.41% dividend yield, but the 73.76 P/E is rich.

Q9: How much does one Aspen Pharmacare Holdings Ltd. share cost?
Answer: One Aspen Pharmacare Holdings Ltd. share costs R148.45 today. That price per share sits alongside a market cap of 67.01bn, a P/E ratio of 73.76, and a dividend yield of 1.41%, giving traders a clear reference point.

Q10: How to sell Aspen Pharmacare Holdings Ltd. shares?
Answer: To sell APN, place a sell order through your trading account on the JSE at or near the live price of R148.45. Trading volume of 14 063 suggests active interest, but execution depends on buy-side demand at that moment.

How to Buy Aspen Pharmacare Holdings Ltd. Shares Step by Step

Open a free trading account with a JSE-access broker.

Verify your account via email or phone number.

Set up 2FA for added security.

Complete KYC verification.

Get familiar with the trading dashboard.

Deposit funds into your account.

Buy Aspen Pharmacare Holdings Ltd. shares using APN.

Aspen Pharmacare Holdings Ltd. Actionable Financial Advice

Given Aspen Pharmacare Holdings Ltd.'s current performance, investors should HOLD the shares if prices move BELOW R148.45 and consider BUY only if price strength improves above that level. Monitor macroeconomic developments, JSE healthcare sentiment, and the company’s valuation to refine your strategy.

Background of Aspen

Aspen did not start as a giant pharmaceutical group. The business started trading from Greyville in Durban in 1997. Aspen Healthcare began trading from Greyville, Durban, during 1997, and Stephen Saad and Gus Attridge were two of its four founders. During 1998, Aspen reached the JSE through a reverse listing into Medhold Ltd.

The present business also draws on the older Lennon history. The business that later became Lennon began in Port Elizabeth in 1850.

Aspen bought South African Druggists’ pharmaceutical business in 1999, bringing that history into the group.

Aspen separates the business into Commercial Pharmaceuticals and Manufacturing. Commercial Pharmaceuticals is divided into prescription medicines, over-the-counter products, and injectables. Manufacturing is reported separately.

Aspen Shares Growth Driver

By 31 December 2025, revenue was R21.085 billion, gross profit was R9.584 billion, operating profit was R2.700 billion, and normalised EBITDA was R5.053 billion.

Commercial Pharmaceuticals brought in more revenue and more normalised EBITDA, at R16.586 billion and R4.845 billion. Manufacturing weakened, with revenue of R4.499 billion and normalised EBITDA well below the R1.265 billion reported before.

The earlier half-year had about R1.5 billion from a manufacturing contract for mRNA products that was later cancelled. The current result received roughly R500 million after the dispute over that contract was settled.

The six months also recorded R695 million in once-off restructuring costs for sterile finished-dose facilities in South Africa and France.

Once APAC was removed, revenue from continuing operations was R17.078 billion, against a restated R17.849 billion. Continuing normalised EBITDA was R3.802 billion, compared with R4.407 billion.

Commercial Pharmaceuticals accounted for R12.825 billion of continuing revenue. Manufacturing was responsible for R4.253 billion.

Australia, New Zealand, and the Asia-Pacific markets outside China were included in the APAC sale. The transaction closed on 29 May 2026, after Mondi’s half-year reporting date. The consideration was AUD2.37 billion. Aggregate net proceeds were about R27 billion.

Aspen Group Investor Tip

The 2025 annual financial statements record 446,252,332 ordinary shares in issue. Mondi’s employee share trusts held 2,229,779 treasury shares. For the half-year earnings per share calculation, the share count used was 444.6 million on a weighted average basis.

The 2025 dividend was lower than the prior year’s. It came to 211 cents a share, paid on 6 October 2025, compared with 359 cents a year earlier. Normalised HEPS was 1,055.8 cents, which put the payout at 20%.

The debt position improved between June and December 2025. Net debt fell from R31.2 billion to R28.6 billion, while net debt to EBITDA was 3.4x before proceeds from the APAC deal came through.

Aspen Major Shareholders

The most recent shareholder schedule is dated 30 June 2025.

The Government Employees Pension Fund owned 20.2% of issued shares.

Stephen Saad owned 13.2%.
Michael Attridge owned 4.3%.
CEPPWAWU Investments owned 2.3%.

Broker	Deposit	Sign Up
	Minimum Deposit: $100	Visit Now
	Minimum Deposit: $10	Visit Now
	Minimum Deposit: $100	Visit Now
	Minimum Deposit: $0	Visit Now